Day: February 26, 2025

Annual Report of Jyske Realkredit A/S for the financial year 2024 To NASDAQ Copenhagen A/S                                                                                                                  26 February 2025                                                                                                                 Announcement no. 18/2025 Annual Report of Jyske Realkredit A/S for the financial year 2024 On February 26, 2025, the Board of Directors has approved the Annual Report of Jyske Realkredit A/S for the financial year 2024. Please see attached files. Yours sincerely,Jyske Realkredit A/S Carsten Tirsbæk MadsenCEO Direct phone (+45) 89 89 90 50E-mail ctm@jyskerealkredit.dk Web: jyskerealkredit.com Please observe that the Danish version of this announcement prevails. Attached files:Jyske Realkredit Preliminary announcement...

COMPANY ANNOUNCEMENT No. 201/2025         Tvis, 26 February 2025 Interim report Q4 2024 (October 1 – December 31) (All figures in brackets refer to the corresponding period in 2023 – AUBO Production A/S is incl.in the figures as from 3 July 2023) B2C sales recovery amid challenging B2B market conditions. CEO Torben Paulin:“Sales in the fourth quarter developed as expected, with declining B2B project sales and a solid uplift in B2C sales. Organically, sales in the quarter declined by 2% year on year to DKK 301 million, as the de-cline in B2B project sales was only partially recouped through B2C sales growth of more than 5% year on year. Full-year revenue was DKK 1,204 million and therefore at the top end of our financial guidance. Order intake in B2C developed positively in the fourth quarter with double-digit growth y-o-y, while...

Highlights financial year 2024Orderbook stands at 8.2 billion euro at the end of the year, up from 7.6 billion euro a year ago Group turnover grew 25% year-over-year to 4.1 billion euro, with solid growth in all contracting segments EBITDA rose 28% reaching 764 million euro, or 18.6% of turnover, up from 596 million euro, or 18.2% of turnover for 2023 Net profit increased by 77%, reaching 288 million euro, compared to 163 million euro a year ago Unprecedented free cash flow generation in 2024, amounting to 729 million euro; resulting in a net cash position of 91 million euro at year-end from a net financial debt of 512 million euro at the end of 2023 Proposal for a gross dividend of 3.8 euro per share, compared to 2.1 euro a year agoAttachmentP2025 DEME 2024 results ENG

JDE Peet’s delivered strong 2024 results, exceeding elevated H1 guidance Increases shareholder returns through higher dividend and multi-year share buyback plan PRESS RELEASE Amsterdam, 26 February 2025 Key items1Organic sales up +5.3%, driven by 4.5% price and 0.7% volume/mix; Reported sales up 7.9% Organic adjusted gross profit up +6.1%; Reported gross profit up +7.9% Organic adjusted EBIT up +10.4% to EUR 1.3 billion Free cash flow of EUR 1,044 million; Net leverage at 2.7x Proposal to increase cash dividend by 4.3% to EUR 0.73 per share Intention to launch multi-year share buyback programme of up to EUR 1 bn, with EUR 250 mln in 2025A message from Rafa Oliveira, CEO of JDE Peet’s “We are very pleased with this strong set of broad-based results, especially considering the increased green coffee inflation. Innovation, driven...

  P R E S S  R E L E A S E Stockholm, February 26, 2025 Rebound continued for BTS Europe and good momentum for our AI tools October 1 – December 31, 2024Net sales MSEK 796 (768). Currency adjusted growth 3%, whereof 0% was organic. EBITA –2%, MSEK 136 (139). EBITA margin 17.0 (18.1) %. Profit after tax amounted to MSEK 84 (110). Excluding reversed provisions of earn-out, the profit after tax increased 1 percent to 82 (81). 1) Earnings per share amounted to SEK 4.31 (5.66). 2) Excluding reversed provision of earn-out, earnings per share increased 1% to SEK 4.24 (4.20). 1)January 1 – December 31, 2024Net sales MSEK 2,802 (2,683). Currency adjusted growth +5%, whereof 3% was organic. EBITA +6 %, MSEK 365 (346). EBITA margin 13.0 (12.9) %. Profit after tax amounted to MSEK 387 (215). Excluding reversed provision of earn-out, the profit...

FY 2024 RESULTSRefocus and rebound underway FY24 results€4,632m revenue, +0.5% organic growth, of which +1.9% in Merchant Services€1,070m adjusted EBITDA€201m free cash-flow, or 19% adjusted EBITDA conversion rate€434m Normalized Net Income group share€(297)m reported Net Income group share1 2025: leveraging Worldline’s repositioning to start the rebound New product developments to accelerate in H2’25with renewed leadership team in MSStrict focus on cost control while leveraging Power24 to improve unlevered free cash flowPortfolio pruning well underway Solid balance sheet and liquidity profileActive management of debt maturity profile while maintaining strong liquidity (successful issuance of a €500m 5-year bond and RCF maturity extended) Worldline appoints Pierre-Antoine Vacheron as Chief Executive Officer30 years of extensive experience...

KALDVIK AS (KLDVK) reports Operating income in Q4 amounted to EURm 46.8 (EURm 32.6), while the operating profit/loss before fair value adjustment of biomass and production tax was EURm -18.1 (EURm 4.6). Operating profit/loss before fair value adjustment of biomass, one-off biomass write-down and production tax was EURm 5.0 (EURm 4.6). Harvest amounted to 6.668 tonnes in Q4 2024 (4.202 tonnes) Web cast will be at 11:00 (CET)/ 10:00 Icelandic time on 26 February 2025 on the following link: www.kaldvik.is/live Attached is the presentation and report for Q4 2024. Kaldvik, 26 February 2025 Contacts: Robert Robertsson, CFO of KALDVIK AS: +354 843 0086(mobile) This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsKaldvik AS – Q4 2024 Quarterly...

Ad hoc announcement pursuant to Art. 53 LRMore than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia’s outstanding convertible bond debt – allowing the removal of a large debt overhang and providing CHF 150 million of new funding Agreement with Viatris to revise collaboration for selatogrel and cenerimod results in the removal of significant cash requirement for 2025 Release from exclusivity constraint allows Idorsia to pivot to negotiate with alternative parties for the global rights to aprocitentan Idorsia to host an investor webcast today, at 15:00 CET Full Year 2024 Financial Reporting and publication of the Financial Report to be postponed to March 4, 2025Allschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that it has reached an agreement...

Bigbank’s gross loan portfolio reached a record 2.2 billion euros at the end of the year, increasing by 137 million euros (+7%) quarter on quarter and by 535 million euros (+32%) year on year. The focus product lines showed solid quarter-on-quarter growth. The business loan portfolio grew by 61 million euros (+9%) to 764 million euros and the home loan portfolio by 79 million euros (+15%) to 613 million euros. The consumer loan portfolio decreased by 9 million euros (-1%) quarter on quarter to 828 million euros. Bigbank’s deposit portfolio grew in the fourth quarter mainly through term deposits. During the quarter, the term deposit portfolio grew by 118 million euros to 1.36 billion euros (+10%) and the savings deposit portfolio by 8 million euros to 1.03 billion euros (+1%). The Group’s total deposit portfolio grew by 127 million euros...

Ad hoc announcement pursuant to Art. 53 LRIdorsia’s contribution to the development costs reduced by USD 100 million Viatris potential regulatory and sales milestones payments to Idorsia reduced by USD 250 millionAllschwil, Switzerland – February 26, 2025Idorsia Ltd (SIX: IDIA) today announced that it has reached an agreement with Viatris Inc. (NASDAQ: VTRS) to update the terms of the global development and commercialization collaboration for selatogrel and cenerimod. In exchange for a USD 100 million reduction to Idorsia’s contribution to the development costs due in 2025, Idorsia has agreed to a USD 250 million reduction in future potential regulatory and sales milestone payments, and an expansion of territorial rights to Viatris for cenerimod. The agreed royalties on future sales remain unchanged. About the collaboration agreementOn...